NBE Therapeutics AG, a biopharmaceutical company developing next generation ADC products based on its Transpo-mAbTM antibody platform, site-specific SMACTM conjugation technology and novel ultra-potent toxin platform today announced the appointment of Hans-Peter Gerber to its Board of Directors.
Hans-Peter has more than 20 years of research and development experience in the field of antibody-drug conjugates (ADC). Most recently he was CSO of Pfizer’s Bioconjugates division where he was leading Pfizer’ s efforts in the ADC field. He also held senior leadership positions at Seattle Genetics and Genentech. Hans-Peter is currently CSO and President at the immune-oncology company Maverick Therapeutics, Inc,.
Hans-Peter is an internationally recognized leader in Oncology drug development, with a strong record of accomplishments in the field of antibody-based targeted therapeutics. His work led to more than six IND filings for ADCs and contributing to BLA submissions of therapeutic antibodies and two ADCs. He is an author on over 90 peer-reviewed published papers and inventor on 15 patents in the field of oncology.
Theo Walthie, Chairman of the Board of NBE-Therapeutics added:
“We are excited that NBE-Therapeutics’ Board of Directors will be complemented by such a high-caliber expert and senior executive in the field of targeted cancer therapeutics with particular expertise in ADC development. This represents an enormous validation of our activities and will expedite the transition of our preclinical ADC development programs into the clinic”
Hans-Peter Gerber added:
“I have been very impressed by the ADC platform of NBE, which has the potential to generate innovative, differentiated and superior antibody drug conjugates with a very unique mode of action. I look forward to working with NBE’s Board and the Executive Team to build a successful company and delivering improved treatment options to cancer patients.”
About NBE Therapeutics AG
NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company, founded in 2012 with the vision of developing next-generation ADC products. NBE advances it’s products to clinical proof of concept with the goal of improving treatment options for cancer patients. The company leverages proprietary platforms covering all aspects of ADC development: its Transpo-mAb DisplayTM technology for antibody discovery, its SMAC-TechnologyTM for site-specific payload conjugation of toxins to antibodies and a novel ultra-potent anthracycline-based toxin platform. The company is financially backed by PPF Group and Boehringer Ingelheim Venture Fund as institutional investors, and by additional Swiss, German and Dutch private investors. For more information about NBE, visit the website http://www.nbe-therapeutics.com